Ellen Ypma

2.1k citations

23 papers · 1.7k indexed · h-index 15

Impact in

Microbiology top 0.2%
- Bacterial Infections and Vaccines
Epidemiology top 2%
- Pneumonia and Respiratory Infections
- Influenza Virus Research Studies
- Respiratory viral infections research
- Virology and Viral Diseases

Papers in ⓘ

Epidemiology 22
- Pneumonia and Respiratory Infections 17
- Influenza Virus Research Studies 6
- Respiratory viral infections research 5
- Virology and Viral Diseases 4
Microbiology 18
- Bacterial Infections and Vaccines 18

Co-authors: Daniela Toneatto (8 shared papers)Audino Podda (3 shared papers)Karl G. Nicholson (2 shared papers)Maria Zambon (2 shared papers)Iain Stephenson (2 shared papers)John Wood (2 shared papers)Philipp Oster (11 shared papers)Peter Dull (5 shared papers)
Journals: Vaccine (4 papers)Archives of Disease in Childhood (3 papers)The Pediatric Infectious Disease Journal (3 papers)JAMA (2 papers)Human Vaccines (2 papers)
Partner nations: Italy United Kingdom New Zealand

In The Last Decade

Ellen Ypma

23 papers receiving 1.6k citations

Peers

Countries citing papers authored by Ellen Ypma

Since Specialization

Citations

This map shows the geographic impact of Ellen Ypma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Ypma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Ypma more than expected).

Fields of papers citing papers by Ellen Ypma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Ypma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Ypma. The network helps show where Ellen Ypma may publish in the future.

Co-authors

The 25 scholars most cited alongside Ellen Ypma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ellen Ypma Line = papers co-authored together Ellen Ypma links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza The Lancet ·Karl G. Nicholson, Anthony Colegate, Audino Podda, Iain Stephenson, John Wood, Ellen Ypma, Maria Zambon	2001	359
2	Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy Clinical Infectious Diseases ·Jamie Findlow, Ray Borrow, Matthew D. Snape, Tom Dawson, Ann Holland, Tessa M. John, A. E. J. Evans, Karen L. Telford, Ellen Ypma, Daniela Toneatto, Philipp Oster, Elizabeth Miller, Andrew J. Pollard	2010	226
3	Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules JAMA ·Nicoletta Gossger, Matthew D. Snape, Ly‐Mee Yu, Adam Finn, Gianni Bona, Susanna Esposito, Nicola Principi, Javier Díez‐Domingo, Étienne Sokal, Birgitta Becker, Dorothee Kieninger, Roman Prymula, Peter Dull, Ellen Ypma, Daniela Toneatto, Alan Kimura, Andrew J. Pollard, for the European MenB Vaccine Study Group	2012	217
4	Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials The Lancet ·Timo Vesikari, Susanna Esposito, Roman Prymula, Ellen Ypma, Igor Kohl, Daniela Toneatto, Peter Dull, Alan Kimura	2013	209
5	Immunogenicity of Two Investigational Serogroup B Meningococcal Vaccines in the First Year of Life The Pediatric Infectious Disease Journal ·Matthew D. Snape, Tom Dawson, Philipp Oster, A. E. J. Evans, Tessa M. John, Brigitte Ohene-Kena, Jamie Findlow, Ly‐Mee Yu, Ray Borrow, Ellen Ypma, Daniela Toneatto, Andrew J. Pollard	2010	159
6	Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population Vaccine ·Iain Stephenson, Karl G. Nicholson, Anthony Colegate, Audino Podda, John Wood, Ellen Ypma, Maria Zambon	2003	132
7	Lymphocyte Counts Independently Predict Overall Survival in Advanced Cancer Patients: A Biomarker for IL-2 Immunotherapy Journal of Immunotherapy ·Luca Fumagalli, Jan Vinke, W G van 't Hoff, Ellen Ypma, Ferdinando Brivio, Angelo Nespoli	2003	77
8	The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans Human Vaccines ·Daniela Toneatto, Shevqet Ismaili, Ellen Ypma, Kay Vienken, Philipp Oster, Peter Dull	2011	71
9	Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand Vaccine ·Philipp Oster, Jane O’Hallahan, Ingeborg S. Aaberge, Sandrine Tilman, Ellen Ypma, Diana Martin	2007	62
10	Immunogenicity and Tolerability in Infants of a New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine The Pediatric Infectious Disease Journal ·Sharon Wong, Diana Lennon, Catherine Jackson, Joanna Stewart, Stewart Reid, Ellen Ypma, Jane O’Hallahan, Philipp Oster, Kim Mulholland, Diana Martin	2009	28
11	Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults Human Vaccines ·Daniela Toneatto, Philipp Oster, A Corine W deBoer, Amy E. Emerson, George França dos Santos, Ellen Ypma, Lisa DeTora, Mariagrazia Pizza, Alan Kimura, Peter Dull	2011	28
12	Immunogenicity, Reactogenicity, and Safety of a P1.7b,4 Strain-Specific Serogroup B Meningococcal Vaccine Given to Preteens Clinical and Vaccine Immunology ·Jamie Hosking, Kumanan Rasanathan, Florina Chan Mow, Catherine Jackson, Diana Martin, Jane O’Hallahan, Philipp Oster, Ellen Ypma, Stewart Reid, Ingeborg S. Aaberge, Sue Crengle, Joanna Stewart, Diana Lennon	2007	23
13	Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers Archives of Disease in Childhood ·C. Jackson, Diana Lennon, Sui H. Wong, Jing Yan, Joanna Stewart, S Reid, Philipp Oster, Ellen Ypma, DR Martin	2011	21
14	Phase II meningococcal B vesicle vaccine trial in New Zealand infants Archives of Disease in Childhood ·Claire Jackson, Diana Lennon, V T K Sotutu, Jing Yan, John Stewart, S Reid, Sue Crengle, Philipp Oster, Ellen Ypma, Ingeborg S. Aaberge, Kim Mulholland, Diana Martin	2008	21
15	Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration The Pediatric Infectious Disease Journal ·Roberto Gasparini, Miguel Tregnaghi, Pavitra Keshavan, Ellen Ypma, Linda K. Han, Igor Smolenov	2015	17
16	Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infants Vaccine ·Heinz-J. Schmitt, Katrin Steul, Astrid Borkowski, Francesca Ceddia, Ellen Ypma, Markus Knuf	2008	10
17	Combined administration of serogroup B meningococcal vaccine and conjugated serogroup C meningococcal vaccine is safe and immunogenic in college students Epidemiology and Infection ·Jennifer Holmes, Diana Martin, C. M. Ramsay, Ellen Ypma, Philipp Oster	2007	10
18	Combined Administration of Meningococcal Serogroup B Outer Membrane Vesicle Vaccine and Conjugated Serogroup C Vaccine Indicated for Prevention of Meningococcal Disease Is Safe and Immunogenic Clinical and Vaccine Immunology ·Ingeborg S. Aaberge, Philipp Oster, Oddveig S. Helland, Anne-Cathrine Kristoffersen, Ellen Ypma, E. Arne Høiby, Berit Feiring, Hanne Nøkleby	2005	8
19	Dose range evaluation of a new inactivated hepatitis A vaccine administered as a single dose followed by a booster Vaccine ·M Minutello, Carla Maria Zotti, Sara Orecchia, Erica di Martino, I Bastianoni, Ellen Ypma, Angela Moiraghi, Audino Podda	2000	6
20	Increased immunogenicity with an MF59-adjuvanted influenza vaccine (FLUAD®) compared with a conventional subunit vaccine (Agrippal®) in renal transplant recipients International Congress Series ·M. Pollok, Helmut Geiger, J. Floege, Ralf Paschke, D. Abendroth, Ulrich Bienzle, Ellen Ypma, Angelika Banzhoff	2004	5

About Ellen Ypma

Ellen Ypma is a scholar working on Epidemiology, Microbiology, Public Health, Environmental and Occupational Health, Immunology and Infectious Diseases, having authored 23 papers that have together received 1.7k indexed citations. Recurring topics across this work include Bacterial Infections and Vaccines (18 papers), Pneumonia and Respiratory Infections (17 papers), Influenza Virus Research Studies (6 papers), Respiratory viral infections research (5 papers), Virology and Viral Diseases (4 papers), Immune Response and Inflammation (3 papers), Neonatal and Maternal Infections (3 papers) and Animal Disease Management and Epidemiology (2 papers). The work is most often cited by research in Microbiology (1.0k citations), Epidemiology (1.5k citations), Agronomy and Crop Science (160 citations), Infectious Diseases (254 citations) and Immunology (279 citations). Ellen Ypma has collaborated with scholars based in Italy, United Kingdom and New Zealand. Frequent co-authors include Daniela Toneatto, Audino Podda, Karl G. Nicholson, Maria Zambon, Iain Stephenson, John Wood, Philipp Oster, Peter Dull, Andrew J. Pollard and Matthew D. Snape. Their work appears in journals such as Vaccine, Archives of Disease in Childhood, The Pediatric Infectious Disease Journal, JAMA and Human Vaccines.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact